AbbVie Inc vs iShares TIPS Bond ETF — how do they compare? AbbVie Inc trades at $250.31 (market cap $438.19B), while iShares TIPS Bond ETF trades at $106.87. The key difference: AbbVie Inc pays a 2.79% dividend while iShares TIPS Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | TIP | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Fixed Income |
52-Week High | $263.58 | $112.20 |
52-Week Low | $197.38 | $106.86 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.19, up 1.28% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust immunology drug performance from Skyrizi and Rinvoq are offsetting Humira patent losses, driving revenue growth to $61.16B in 2025. The stock is near its pivot point of $247, with support at $245 and resistance at $249.
The outlook remains positive with a consensus price target of $281.33, though high P/E of 70.05 and looming patent cliffs in the 2030s present risks. Dividend growth and institutional accumulation support the buy case, but margin compression and debt levels warrant monitoring.
TIP trades at $107.08 with minimal daily movement (+0.2%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces headwinds from broader market concerns about inflation and Federal Reserve policy. Recent dividend distributions provide some shareholder return, but key financial ratios remain undisclosed, limiting fundamental visibility.
Outlook remains cautious due to bearish technicals and macroeconomic uncertainty. Investment opportunity hinges on inflation trends and Fed policy clarity, while risks include prolonged bond market volatility and energy price impacts. Wall Street sentiment appears mixed with technical weakness offset by dividend stability.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →